Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Shares Soared Today

By Keith Speights – Jun 1, 2020 at 3:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked an analyst's higher price target for the biotech stock.

What happened

Shares of Novavax (NVAX -10.14%) were soaring 14.9% as of 3 p.m. EDT on Monday. The big jump came after B. Riley FBR analyst Mayank Mamtani boosted his 12-month price target on the biotech stock to $61 per share from $53. 

So what

Investors should take analysts' price targets with a grain of salt. However, it's good to understand what influences analysts' thinking. 

COVID-19 vaccine leaning against a tiny house with a doctor in the background

Image source: Getty Images.

In this case, Mamtani believes that Novavax's recently announced acquisition of Praha Vaccines will enable the small biotech to go head to head with larger drugmakers who are also racing to develop a COVID-19 vaccine. He also views Novavax's experimental COVID-19 vaccine as one of the most promising candidates in development. Mamtani stated that Novavax's NVX‑CoV2373 has "the most extensive/differentiated preclinical data generated to date."

Novavax's acquisition of Czech-based Praha Vaccines for $167 million should enable the company to produce more than 1 billion doses of its COVID-19 vaccine candidate next year. The company is paying for this acquisition with the $388 million investment that Coalition for Epidemic Preparedness Innovations (CEPI) is making to fund its COVID-19 vaccine program.

Now what

The main thing to watch for now with Novavax is its phase 1 study of NVX‑CoV2373. Novavax initiated this study last week and expects to report preliminary immunogenicity and safety results in July.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.87 (-10.14%) $-2.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.